Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Current Liabilities (2019 - 2026)

Pliant Therapeutics has reported Total Current Liabilities over the past 8 years, most recently at $10.4 million for Q1 2026.

  • Quarterly Total Current Liabilities fell 63.27% to $10.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Mar 2026, down 63.27% year-over-year, with the annual reading at $16.4 million for FY2025, 50.73% down from the prior year.
  • Total Current Liabilities was $10.4 million for Q1 2026 at Pliant Therapeutics, down from $16.4 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $40.0 million in Q3 2024 and troughed at $10.4 million in Q1 2026.
  • The 5-year median for Total Current Liabilities is $26.2 million (2022), against an average of $25.1 million.
  • Year-over-year, Total Current Liabilities skyrocketed 106.3% in 2022 and then plummeted 63.27% in 2026.
  • A 5-year view of Total Current Liabilities shows it stood at $23.9 million in 2022, then grew by 19.28% to $28.5 million in 2023, then increased by 16.46% to $33.2 million in 2024, then plummeted by 50.73% to $16.4 million in 2025, then crashed by 36.7% to $10.4 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Total Current Liabilities are $10.4 million (Q1 2026), $16.4 million (Q4 2025), and $17.6 million (Q3 2025).